K7D8Y1 (K7D8Y1_PANTR) Pan troglodytes (Chimpanzee)
CHK2 checkpoint homolog UniProtKBInterProInteractive Modelling
543 aa; Sequence (Fasta) ;
1 identical sequence: Homo sapiens: O96017
It is possible new templates exist for this target since these models were created.
Available Structures
38 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal structure of the mammalian MDC1 FHA domain complexed with CHK2 pThr68 peptide |
Heteromer O96017; Q5PSV9; | 100 | ||||
| Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase | homo-2-mer | 99.74 | ||||
| Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase | homo-2-mer | 99.73 | ||||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | homo-2-mer | 100.0 | 2×HAU; 2×NO3; 2×CL; 14×EDO; | |||
| CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR | homo-2-mer | 100.0 | 2×NO3; 18×EDO; 2×A9U; 2×CL; | |||
| CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR | homo-2-mer | 100.0 | 2×A9T; 2×NO3; 6×EDO; | |||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | homo-2-mer | 100.0 | 2×NO3; 2×WVI; 6×EDO; 2×CL; | |||
| CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR | homo-2-mer | 100.0 | 2×NO3; 2×RU5; 2×EDO; | |||
| CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR | homo-2-mer | 100.0 | 2×NO3; 2×RU9; | |||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | homo-2-mer | 100.0 | 6×EDO; 2×Z0O; 2×NO3; | |||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | homo-2-mer | 100.0 | 2×H3R; 2×NO3; 4×EDO; | |||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | homo-2-mer | 100.0 | 2×P3J; 2×NO3; 2×EDO; 2×CL; | |||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | homo-2-mer | 100.0 | 2×Z2M; 2×NO3; | |||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | homo-2-mer | 100.0 | 2×RQQ; 2×NO3; 6×EDO; | |||
| Crystal Structure of Chk2 in complex with an inhibitor | homo-2-mer | 100.0 | 2×XBJ; 2×MG; 4×NO3; | |||
| Structure of a small molecule inhibitor with the kinase domain of Chk2 | homo-2-mer | 100.0 | 2×LWH; 2×NO3; | |||
| Crystal Structure of Checkpoint Kinase 2 in complex with Inhibitor PV1531 | homo-2-mer | 100.0 | 2×YCF; 2×MG; 2×NO3; | |||
| Cellular inhibition of checkpoint kinase 2 and potentiation of cytotoxic drugs by novel Chk2 inhibi… | homo-2-mer | 100.0 | 2×D1A; 2×MG; 2×NO3; 4×EDO; | |||
| Crystal structure of checkpoint kinase 2 in complex with PV788 | homo-2-mer | 100.0 | 2×NXP; 2×NO3; | |||
| Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1322 | homo-2-mer | 100.0 | 2×YIQ; 2×NO3; | |||
| Crystal structure of checkpoint kinase 2 in complex with inhibitor PV1115 | homo-2-mer | 100.0 | 2×UPX; 2×NO3; | |||
| Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1352 | homo-2-mer | 100.0 | 2×YIR; 2×NO3; | |||
| Structural analysis of checkpoint kinase 2 in complex with PV1162, a novel inhibitor | homo-2-mer | 100.0 | 2×YIT; 2×NO3; | |||
| Crystal structure of checkpoint kinase 2 in complex with inhibitor PV976 | homo-2-mer | 99.64 | 2×HCW; 2×NO3; | |||
| Structural analysis of checkpoint kinase 2 (Chk2) in complex with inhibitor PV1533 | homo-2-mer | 100.0 | 2×XK9; | |||
| Crystal structure of human Chk2 in complex with ADP | homo-2-mer | 99.64 | 2×CL; 4×MG; 2×NO3; 2×ADP; | |||
| Co-crystal structure of a small molecule inhibitor bound to the kinase domain of Chk2 | homo-2-mer | 100.0 | 2×B4W; | |||
| Crystal structure of human Chk2 in complex with debromohymenialdisine | homo-2-mer | 100.0 | 2×MG; 2×NO3; 2×DBQ; | |||
| CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR | monomer | 99.65 | 1×WTJ; 2×NO3; 4×EDO; | |||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | monomer | 100.0 | 1×NO3; 9×EDO; 1×ODO; | |||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | monomer | 100.0 | 1×NO3; 4×EDO; 1×CWS; | |||
| CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR | monomer | 100.0 | 1×WTI; 2×NO3; 2×EDO; | |||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | monomer | 100.0 | 1×NO3; 7×EDO; 1×VFB; 1×CL; | |||
| Crystal structure of Chk2 in complex with an inhibitor | monomer | 100.0 | 1×ZZK; 1×NO3; 3×EDO; | |||
| Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) | monomer | 100.0 | 1×ODH; 1×NO3; 1×CL; 1×EDO; | |||
| CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR | monomer | 100.0 | 1×VGM; 1×NO3; | |||
| Crystal structure of Chk2 in complex with NSC 109555, a specific inhibitor | monomer | 100.0 | 1×ZAT; 1×NO3; | |||
| FHA domain from human Chk2 kinase in complex with a synthetic phosphopeptide | monomer | 100 | ||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3i6w.1.A | homo-2-mer | 0.79 | 99.77 | |||
| 4wb7.2.A | monomer | 0.67 | 1×ZN; | 35.82 | ||